Stock LSL LSL PHARMA GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

LSL Pharma Group Inc. Stock

Equities

LSL

CA50190N1042

Pharmaceuticals

End-of-day quote Toronto S.E.
Other stock markets
 18:00:00 2024-06-24 EDT 		5-day change 1st Jan Change
0.48 CAD 0.00% Intraday chart for LSL Pharma Group Inc. -2.04% -1.03%
06-18 LSL Pharma Group Inc. acquired Virage Santé inc. CI
06-05 LSL Pharma to Raise $4.5 Million Via Private Placements MT

Financials

Sales 2022 8.21M 6.01M Sales 2023 10.03M 7.34M Capitalization 39.98M 29.26M
Net income 2022 -8M -5.86M Net income 2023 -8M -5.86M EV / Sales 2022 * -
Net Debt 2022 12.69M 9.29M Net Debt 2023 16.26M 11.9M EV / Sales 2023 5.61 x
P/E ratio 2022 *
-
P/E ratio 2023
-4.6 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 75.43%
More Fundamentals * Assessed data

Chart LSL Pharma Group Inc.

Dynamic Chart

Latest news about LSL Pharma Group Inc.

LSL Pharma Group Inc. acquired Virage Santé inc. CI
LSL Pharma to Raise $4.5 Million Via Private Placements MT
LSL Pharma Group Inc. announced that it expects to receive CAD 3 million in funding CI
LSL Pharma Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
LSL Pharma to Acquire Quebec Competitor for $2.5 Million to Expand Natural-Product Offerings MT
LSL Pharma Group Inc. entered into a binding Letter of Intent to acquire Target Co for CAD 2.5 million. CI
LSL Pharma Group Brief: Said Earlier Wednesday It Secured $3.8 Million As the Second And Final Tranche Of Its Private Placement Of Units MT
LSL Pharma Group Inc. announced that it has received CAD 6.479426 million in funding from Alfera Pharmaceuticals, LLC CI
LSL Pharma Group Inc. Appoints Diane Beaudry and Mario Paradis to Its Board of Directors CI
LSL Pharma Group Brief: Has Upsized Its Private Placement From $3.5 Million To $7.5 Million MT
LSL Pharma Loses 5% As Raises $6.44 Million In First Closing Of Private Placements MT
LSL Pharma Raises $6.44 Million In First Closing Of Private Placements MT
LSL Pharma Group Inc. announced that it expects to receive CAD 3.5 million in funding CI
LSL Pharma Group Announced An Extension Of Its Convertible Debentures Offering MT
LSL Pharma Group Up 4.7% After Reporting Closing of Second Tranche of Convertible Debentures Offering MT
More news

Press releases LSL Pharma Group Inc.

LSL Pharma Group Completes the Acquisition of Virage Santé GL
LSL Pharma Group Completes the Acquisition of Virage Santé AQ
LSL Pharma Group Announces Engagement of Red Cloud Securities GL
LSL Pharma Group Announces Engagement of Red Cloud Securities AQ
LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $4.5 Million GL
More press releases

News in other languages on LSL Pharma Group Inc.

Gestion Jacques Grimard Inc. acquiert des unités de Groupe LSL Pharma Inc.
Le Groupe LSL Pharma clôture un financement de 6,44 millions $ comme première tranche de placements privés concomittants sans courtier
Le groupe LSL Pharma annonce une combinaison de placements privés pour un produit brut total maximum de 8 millions $
Le Groupe LSL Pharma annonce la prolongation de son placement de débentures convertibles
Le Groupe LSL Pharma annonce la clôture de la deuxième tranche du placement de débentures convertibles
More news

Quotes and Performance

1 week-2.04%
Current month-5.88%
1 month-4.00%
3 months+20.00%
6 months+6.67%
Current year-1.03%
More quotes

Highs and lows

1 week
0.45
Extreme 0.45
0.49
1 month
0.45
Extreme 0.45
0.53
Current year
0.35
Extreme 0.35
0.55
1 year
0.35
Extreme 0.35
0.55
3 years
0.35
Extreme 0.35
1.00
5 years
0.35
Extreme 0.35
1.00
10 years
0.35
Extreme 0.35
1.00
More quotes

Quotes

Date Price Change Volume
24-06-25 0.48 0.00% 2,282
24-06-24 0.48 -1.03% 1,000
24-06-21 0.485 +1.04% 3,000
24-06-20 0.48 -2.04% 103,000
24-06-19 0.49 0.00% 1,500

End-of-day quote Toronto S.E., June 24, 2024

More quotes

Company Profile

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company. The Company is specialized in the development, manufacturing and commercialization of sterile ophthalmic pharmaceuticals, as well as natural health products in solid dosage forms. It specializes in the manufacturing and marketing of natural health products (NHPs). The Company manufactures a range of NHPs in liquid, powder and capsule form, sold under its own brand or under private labels. Its manufacturing activities include blistering, encapsulation, sachet and jar filling. The Company's subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc. and Groupe Immobilier LSL inc.
Sector
Pharmaceuticals
Calendar
2024-06-28 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
LSL PHARMA GROUP INC. Stock LSL Pharma Group Inc.
-1.03% 38.06M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.19% 801B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+47.26% 631B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.09% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.92% 337B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.40% 245B
ROCHE HOLDING AG Stock Roche Holding AG
+3.64% 231B
NOVARTIS AG Stock Novartis AG
+12.98% 219B
AMGEN INC. Stock Amgen Inc.
+10.86% 171B
PFIZER, INC. Stock Pfizer, Inc.
-2.78% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LSL Stock